Home Tags Seattle Genetics

Tag: Seattle Genetics

Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin, also known as ASG-22CE,...
Seattle Genetics

5 Things You Need To Know This Week About ADCs –...

This is the second article in my series of updates about the goings on in the world of ADCs over the last two weeks....
Exhibition booth Seattle Genetics - ASCO 2019 | Courtsey: Emila Duaerte / Sunvalley Communication

Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior...

Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...

Interim Results from Ongoing Studies of Brentuximab Vedotin + Nivolumab in...

Multiple presentations evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda*) across a broad range of Hodgkin lymphoma (HL) settings were presented at the 11th International Symposium...

PharmaMar and Seattle Genetics Sign Licensing Agreement for Fully Synthetic Marine-derived...

Earlier this week PharmaMar, an Madrid-based biopharmaceutical company developing innovative marine-derived anticancer drugs, signed an exclusive agreement with Seattle Genetics in which the company...

Seattle Genetics Enhances Portfolio of Solid Tumor Programs by Acquiring Cascadian...

Two Washington-state based companies, Seattle Genetics and Cascadian Therapeutics (previously named Oncothyreon), a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the...

Phase III ECHELON-1 Clinical Trial of Brentuximab Vedotin Meets Primary Endpoint...

Data from the Phase III ECHELON-1 clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics | Takeda) as part of a frontline combination chemotherapy regimen...

Supplemental Biologics License Application for Brentuximab Vedotin in Frontline Advanced Hodgkin...

Based on positive results from the Phase III ECHELON-1 Clinical Trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...
Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

Phase Ib Trial of Enfortumab Vedotin + Immune Checkpoint Inhibitor Initiated...

Seattle Genetics and Astellas Pharma confirmed the dosing of the first patient in EV-103, a phase Ib clinical trial evaluating the safety and tolerability...